pioglitazone has been researched along with Libman-Sacks Disease in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone could enhance alternative activation of monocyte-derived macrophages and consequently immunomodulation in these patients." | 1.46 | Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone. ( Memarian, A; Mohammadi, S; Saghaeian-Jazi, M; Sedighi, S, 2017) |
| "Pioglitazone-treated mice showed improvement in insulin resistance, adipokine, and lipid profile." | 1.35 | The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. ( Brosius, FC; Hodgin, JB; Kaplan, MJ; Kretzler, M; Park, JL; Pennathur, S; Randolph, A; Somers, EC; Thacker, SG; Wang, JH; Zhang, H; Zhao, W, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mohammadi, S | 1 |
| Saghaeian-Jazi, M | 1 |
| Sedighi, S | 1 |
| Memarian, A | 1 |
| Zhao, W | 2 |
| Berthier, CC | 1 |
| Lewis, EE | 1 |
| McCune, WJ | 1 |
| Kretzler, M | 2 |
| Kaplan, MJ | 2 |
| Aprahamian, TR | 1 |
| Bonegio, RG | 1 |
| Weitzner, Z | 1 |
| Gharakhanian, R | 1 |
| Rifkin, IR | 1 |
| Thacker, SG | 1 |
| Hodgin, JB | 1 |
| Zhang, H | 1 |
| Wang, JH | 1 |
| Park, JL | 1 |
| Randolph, A | 1 |
| Somers, EC | 1 |
| Pennathur, S | 1 |
| Brosius, FC | 1 |
| Juárez-Rojas, JG | 1 |
| Medina-Urrutia, AX | 1 |
| Jorge-Galarza, E | 1 |
| Caracas-Portilla, NA | 1 |
| Posadas-Sánchez, R | 1 |
| Cardoso-Saldaña, GC | 1 |
| Goycochea-Robles, MV | 1 |
| Silveira, LH | 1 |
| Lino-Pérez, L | 1 |
| Mas-Oliva, J | 1 |
| Pérez-Méndez, O | 1 |
| Posadas-Romero, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease[NCT00554853] | Phase 3 | 143 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus, a Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT01322308] | Phase 4 | 30 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This measure represents the percentage change in diameter of brachial artery in response to reactive hyperemia. The data is presented intentionally and only for the results at the conclusion of the study. (NCT00554853)
Timeframe: 8 months
| Intervention | % changes in diameter of artery (Mean) |
|---|---|
| Study Drug (Pioglitazone) Then Placebo | 8.3 |
| Placebo Then Study Drug (Pioglitazone) | 9.43 |
"Quantification of disease activity using validated assessments (disease activity score on 28 joints (DAS28) and and C-reactive protein ( CRP) (Inflammatory marker) as a combined score (DAS-28CRP)).~Mean decrease in DAS-28-CRP score when compared to baseline was measured. The range of DAS-28-CRP is 0-10, with 0 meaning no active disease detected and 10 being the most severe active disease detected by joint count and C-reactive protein levels in blood." (NCT00554853)
Timeframe: 8 mo
| Intervention | mean decrease in DAS28-CRP score (Mean) |
|---|---|
| All Participants While on Placebo | 0.15 |
| All Participants While on Study Drug (Pioglitazone) | .31 |
1 trial available for pioglitazone and Libman-Sacks Disease
| Article | Year |
|---|---|
Pioglitazone improves the cardiovascular profile in patients with uncomplicated systemic lupus erythematosus: a double-blind randomized clinical trial.
Topics: Adult; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Lupus Eryt | 2012 |
4 other studies available for pioglitazone and Libman-Sacks Disease
| Article | Year |
|---|---|
Immunomodulation in systemic lupus erythematosus: induction of M2 population in monocyte-derived macrophages by pioglitazone.
Topics: Adolescent; Adult; Case-Control Studies; Cytokines; Female; Humans; Immunomodulation; Inflammation; | 2017 |
The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus.
Topics: Cell Proliferation; Cells, Cultured; DNA; Gene Expression Profiling; Gene Expression Regulation; Hum | 2013 |
Peroxisome proliferator-activated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus.
Topics: Animals; Apolipoproteins E; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; | 2014 |
The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Endothelium, Vascular; Female; Inflammation Media | 2009 |